Wallace Weitz
Weitz Value Fund
Wallace Weitz Thermo Fisher Scientific Inc stake
total: 53
Weitz Value Fund TMO trades
- Total transactions:
- 12
- New positions:
- 1
- Added:
- 4
- Reduced:
- 7
- Held since:
- 2019 Q3
- Held for:
- 27 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q1 report, Wallace Weitz holds 76,250 Thermo Fisher Scientific Inc (TMO) shares with a market value of roughly $37.48M accounting for 5.96% of the overall portfolio. To date, the estimated cost basis is nearly $330.63 for "buy" trades and estimated average "sell" price is $500.04. Weitz Value Fund first purchased TMO in 2019 Q3, initially acquiring 100,000 shares. Since the initial investment in Thermo Fisher Scientific Inc (TMO), Weitz Value Fund has made 11 more transactions.
When did Wallace Weitz buy Thermo Fisher Scientific Inc (TMO)?
Wallace Weitz first invested in Thermo Fisher Scientific Inc (TMO) in 2019 Q3 at the reported quarter-end price of $291.27 per share.
What's the cost basis of Weitz Value Fund's TMO stake?
The estimated cost basis for Thermo Fisher Scientific Inc (TMO) stake is around $330.63 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $330.62
- Weighted AVG sell price:
- $500.04
Wallace Weitz's historical trades in Thermo Fisher Scientific Inc
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
5.96%
|
76,250
|
$491.53
|
$37,479,162
|
-10.29% (-8,750)
|
-0.57%
|
|
2025 Q4
|
6.49%
|
85,000
|
$579.45
|
$49,253,250
|
-3.41% (-3,000)
|
-0.21%
|
|
2025 Q2
|
4.19%
|
88,000
|
$405.46
|
$35,680,480
|
+17.33% (+13,000)
|
+0.62%
|
|
2023 Q3
|
4.54%
|
75,000
|
$506.17
|
$37,962,750
|
+15.38% (+10,000)
|
+0.61%
|
|
2023 Q2
|
3.98%
|
65,000
|
$521.75
|
$33,913,750
|
+8.33% (+5,000)
|
+0.31%
|
|
2022 Q4
|
4.45%
|
60,000
|
$550.69
|
$33,041,400
|
-7.69% (-5,000)
|
-0.39%
|
|
2022 Q3
|
4.62%
|
65,000
|
$507.19
|
$32,967,350
|
-7.14% (-5,000)
|
-0.33%
|
|
2021 Q4
|
4.48%
|
70,000
|
$667.24
|
$46,706,800
|
-6.67% (-5,000)
|
-0.33%
|
|
2021 Q1
|
3.69%
|
75,000
|
$456.38
|
$34,228,500
|
+2.74% (+2,000)
|
+0.1%
|
|
2020 Q4
|
3.88%
|
$465.78
|
-14.12% (-12,000)
|
|||
|
2020 Q3
|
4.62%
|
$441.52
|
-15.00% (-15,000)
|
|||
|
2019 Q3
|
3.56%
|
$291.27
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.